GTPases such as Ras act as molecular switches to transduce signals from cell surface receptors into pathways regulating cell growth, morphology and movement; their aberrant activation leads to tumorigenesis and invasion. Despite their central role in diseases like cancer and fibrosis, development of drugs that target GTPases has eluded scientists for decades. BellBrook is using proprietary assay technology to discover small molecules that modulate GTPases indirectly, by inhibiting the proteins that control their activation state.
The cGAS/STING pathway activates the immune system in response to foreign and/or damage induced self-DNA. Aberrant activation of cGAS by self-DNA contributes to debilitating and sometimes fatal autoimmune diseases. BellBrook is using a proprietary cGAS enzymatic assay to discover cGAS inhibitors for treatment of rare, monogenic autoimmune diseases and systemic lupus erythematosus (SLE).